Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow the Wegovy tablet works, who it suits, and what the evidence actually shows
The biggest misconception: Wegovy has always been an injection, hasn't it?
Until June 2026, yes. The Wegovy pen has been the only licensed semaglutide product for weight management in the UK since NICE recommended it under TA875. The injection remains available, works through the same biological pathway, and has a longer evidence base. But many people ruled out treatment because weekly injections felt like a barrier, needles, refrigeration, the visible ritual of it. The oral tablet removes all three objections in one go.
The confusion with the word "capsule" is understandable. Some medicines in this class are described loosely as capsules in press coverage, and the distinction between tablet and capsule is rarely explained. For the record: the Wegovy weight-loss product is a film-coated tablet, so if you have come across references to Wegovy capsules elsewhere online, that terminology does not reflect the licensed form. If you want the detail on how the injection and tablet compare, the Wegovy treatment overview covers both formats side by side.
What the tablet is not: it is not Rybelsus. Rybelsus is also oral semaglutide, but at 3mg, 7mg and 14mg doses licenced for type 2 diabetes management, the dose steps and the licensed purpose are entirely different. The Wegovy tablet's 1.5mg to 25mg schedule is its own approved pathway, and the two products should not be conflated.
How the semaglutide tablet reaches your bloodstream
Standard semaglutide breaks down in the stomach before it can be absorbed. The Wegovy tablet gets around this by pairing semaglutide with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) an absorption enhancer that briefly raises the local pH near the stomach lining and lets semaglutide pass through. Bioavailability is lower than with the injection, which is why the tablet dose (up to 25mg) looks much higher than the injection's 2.4mg maintenance; the pharmacological effect is calibrated to deliver a comparable clinical result.
Once absorbed, semaglutide acts on GLP-1 receptors in the brain and gut, reducing appetite, slowing gastric emptying and helping the body regulate blood sugar. You can read more about semaglutide's mechanism in the NHS semaglutide medicines guide. The core appetite-reduction effect is the same whether semaglutide arrives via injection or tablet, the route to the receptor just differs. If you are also researching injectable formats, our guide to the semaglutide ampule explains how that presentation is supplied and used.
Because absorption depends on the stomach environment, the tablet must be taken in a precise way: first thing in the morning, on a completely empty stomach, with a small amount of plain water (roughly up to 120ml). Nothing else (no coffee, no food, no other medicines) for at least 30 minutes afterwards. That 30-minute window is a practical thing to build into your morning before treatment starts. Set a phone reminder, put the pack next to your glass, and use the time before the kettle boils to check the Patient Information Leaflet if anything is unclear.
What the OASIS 4 trial found, and how to read the 17% figure
The headline result from OASIS 4, the pivotal phase-3 trial Novo Nordisk submitted for UK approval, was an average weight loss of approximately 13.6% over 64 weeks among participants taking the 25mg tablet alongside lifestyle changes, compared with around 2.4% in the placebo group. That is the default number to hold in mind. The ~17% figure quoted on some pages (including details from the dosing schedule guide) reflects results specifically among participants who adhered fully to the treatment protocol; it is a real finding from the same trial, but it needs that context to be meaningful. Our Wegovy 1mg dose guide covers the opening step of that schedule in more detail for anyone starting treatment.
Participants were adults with obesity or overweight plus at least one weight-related condition, and none had type 2 diabetes. The most commonly reported side effects were gastrointestinal: nausea, vomiting and diarrhoea affected a majority of participants on the active tablet (around 74%), compared with roughly 42% on placebo. Most cases were mild to moderate and tended to ease as the body adjusted to each dose step. For a fuller account of what the injection trial evidence looks like for comparison, the STEP 1 trial published in the New England Journal of Medicine remains the reference for semaglutide 2.4mg.
As of summer 2026, the Wegovy tablet is not available on the NHS: a NICE appraisal would need to be completed first. It is available privately, on prescription, following a clinical assessment. If you are weighing up the cost of private treatment, the Wegovy pricing guide explains what a legitimate private prescription typically includes and the context around current market pricing.
Who this tablet is licensed for, and what happens next
The MHRA licence covers adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. It is used alongside a reduced-calorie diet and increased physical activity, not instead of them. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance.
The tablet is not licensed for under-18s, is not recommended during pregnancy or breastfeeding, and is not appropriate for anyone trying to conceive. A prescriber will also want to know about other medicines you take, because the 30-minute absorption window affects when other oral drugs can be given. These are the kinds of questions a clinical consultation is designed to work through, a prescriber reads every response personally, not a system. If you are already taking the Wegovy injection and wondering about switching, that is a conversation for your current prescriber first; patients established on the 2.4mg weekly injection may be able to move to the 25mg tablet, but only after clinical review.
For a broader look at how oral and injectable semaglutide sit alongside other options, the weight-loss treatment overview compares the available licensed routes. Our clinical team reviews each case individually, speak to our prescribers if you want to understand whether the tablet might be suitable for you.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.